Researchers identify target to overcome treatment resistance in preclinical models of KRAS-mutant cancers
Researchers identified that RASH3D19 creates a positive feedback loop that drives hyperactivity of RAS signaling and leads to tumor growth and treatment resistance
Reducing RASH3D19 also reduced tumor growth and sensitized cancer cells to KRAS inhibitors
Combining RASH3D19 blockers with KRAS inhibitors improved outcomes in preclinical models
Researchers at The University of Texas MD Anderson Cancer Center have identified a specific...
Study provides comprehensive insights into DNA language models
Researchers examined five AI models on multiple genomic tasks to see how well they performed
Models performed well overall, with each having...